H.R. 3379 · 116th Congress
Price Relief, Innovation, and Competition for Essential Drugs Act
- Stage
- In committee
- Sponsor
- Jan Schakowsky
- Introduced
- 2019-06-20
- Latest action
- 2019-06-21 · Referred to the Subcommittee on Health.
Summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.